Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.

IMPORTANCE Because APOE locus variants contribute to risk of late-onset Alzheimer disease (LOAD) and to differences in age at onset (AAO), it is important to know whether other established LOAD risk loci also affect AAO in affected participants. OBJECTIVES To investigate the effects of known Alzheimer disease risk loci in modifying AAO and to estimate their cumulative effect on AAO variation using data from genome-wide association studies in the Alzheimer Disease Genetics Consortium. DESIGN, SETTING, AND PARTICIPANTS The Alzheimer Disease Genetics Consortium comprises 14 case-control, prospective, and family-based data sets with data on 9162 participants of white race/ethnicity with Alzheimer disease occurring after age 60 years who also had complete AAO information, gathered between 1989 and 2011 at multiple sites by participating studies. Data on genotyped or imputed single-nucleotide polymorphisms most significantly associated with risk at 10 confirmed LOAD loci were examined in linear modeling of AAO, and individual data set results were combined using a random-effects, inverse variance-weighted meta-analysis approach to determine whether they contribute to variation in AAO. Aggregate effects of all risk loci on AAO were examined in a burden analysis using genotype scores weighted by risk effect sizes. MAIN OUTCOMES AND MEASURES Age at disease onset abstracted from medical records among participants with LOAD diagnosed per standard criteria. RESULTS Analysis confirmed the association of APOE with earlier AAO (P = 3.3 × 10(-96)), with associations in CR1 (rs6701713, P = 7.2 × 10(-4)), BIN1 (rs7561528, P = 4.8 × 10(-4)), and PICALM (rs561655, P = 2.2 × 10(-3)) reaching statistical significance (P < .005). Risk alleles individually reduced AAO by 3 to 6 months. Burden analyses demonstrated that APOE contributes to 3.7% of the variation in AAO (R(2) = 0.256) over baseline (R(2) = 0.221), whereas the other 9 loci together contribute to 2.2% of the variation (R(2) = 0.242). CONCLUSIONS AND RELEVANCE We confirmed an association of APOE (OMIM 107741) variants with AAO among affected participants with LOAD and observed novel associations of CR1 (OMIM 120620), BIN1 (OMIM 601248), and PICALM (OMIM 603025) with AAO. In contrast to earlier hypothetical modeling, we show that the combined effects of Alzheimer disease risk variants on AAO are on the scale of, but do not exceed, the APOE effect. While the aggregate effects of risk loci on AAO may be significant, additional genetic contributions to AAO are individually likely to be small.

D. G. Clark | Jason J. Corneveaux | C. Carlson | K. Lunetta | D. Geschwind | H. Hakonarson | J. Buxbaum | J. Haines | M. Pericak-Vance | G. Schellenberg | M. Albert | C. DeCarli | R. Green | L. Schneider | C. Lyketsos | D. Bennett | A. Myers | V. Pankratz | T. Montine | M. Mesulam | R. Petersen | J. Trojanowski | D. Blacker | J. Growdon | B. Hyman | B. Reisberg | J. Hardy | A. Saykin | P. S. St George-Hyslop | J. Becker | R. Albin | D. Mash | A. Levey | J. Kaye | R. Mayeux | M. Sano | B. Boeve | H. Paulson | O. Lopez | L. Apostolova | S. DeKosky | D. Galasko | G. Jicha | E. Masliah | M. Frosch | D. Dickson | J. Parisi | J. Quinn | A. Goate | N. Cairns | B. Ghetti | J. Ringman | E. Reiman | E. Martin | L. Honig | S. Arnold | L. Farrer | M. Barmada | H. Chui | J. Kramer | W. Seeley | K. Welsh-Bohmer | E. Bigio | S. Weintraub | R. Tanzi | M. Gearing | M. Carrasquillo | S. Younkin | Carlos Cruchaga | J. Glass | H. Vinters | Denis A. Evans | P. D. De Jager | W. Kukull | H. Rosen | T. Foroud | P. Crane | D. Beekly | L. Harrell | J. Troncoso | C. Reitz | J. Kauwe | A. Boxer | A. Karydas | M. Huentelman | J. Lah | M. Ganguli | A. McDavid | T. Bird | A. Naj | G. Jun | G. Beecham | T. Thornton-Wells | B. Vardarajan | Chiao-Feng Lin | B. Kunkle | C. Baldwin | M. Kamboh | E. Larson | E. Rogaeva | D. Tsuang | O. Valladares | K. Hamilton-Nelson | K. Faber | L. Cantwell | Li-San Wang | T. Beach | Chang-En Yu | G. Jarvik | J. Vonsattel | R. Rosenberg | N. Graff-Radford | R. Stern | M. Farlow | N. Kowall | C. Hulette | R. Woltjer | E. Roberson | S. Ferris | F. LaFerla | E. Peskind | N. Ertekin-Taner | J. Bowen | W. McCormick | Ge Li | S. McCurry | J. Olichney | F. Demirci | J. Burke | J. Corneveaux | L. Barnes | R. Duara | E. Crocco | W. Mack | E. Head | D. Cribbs | C. Wright | M. Raskind | A. Lieberman | V. V. Van Deerlin | R. Kim | J. Leverenz | L. V. Van Eldik | W. Perry | Amanda G. Smith | R. Hamilton | R. Barber | C. Cao | R. Carney | S. Carroll | M. Dick | K. Fallon | E. Koo | P. Kramer | F. Martiniuk | C. Miller | Joshua W. Miller | J. Murrell | A. Pierce | W. Poon | H. Potter | A. Raj | J. Sonnen | S. Spina | J. Williamson | Lee‐way Jin | Y. Park | Sarah Wishnek | J. Schneider | V. V. van Deerlin | Lei Yu | A. Mckee | J. Gilbert | Ruchita A Rajbhandary | B. Miller | J. Morris | J. Hardy | J. Haines | J. Morris | J. Schneider | F. Y. Demirci | D. Bennett

[1]  P. Crane,et al.  Alzheimer’s Disease: Analyzing the Missing Heritability , 2013, PloS one.

[2]  Toshiko Tanaka,et al.  Alzheimer's disease risk genes and the age-at-onset phenotype , 2013, Neurobiology of Aging.

[3]  D. Harold,et al.  Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome , 2013, Neurobiology of Aging.

[4]  Zhenxin Zhang,et al.  [Correlation between Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a Chinese Han population]. , 2013, Zhonghua yi xue za zhi.

[5]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[6]  M. Daly,et al.  Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.

[7]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[8]  O L Lopez,et al.  Genome-wide association analysis of age-at-onset in Alzheimer's disease , 2012, Molecular Psychiatry.

[9]  A. Goate,et al.  Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains , 2012, PloS one.

[10]  Naomi R. Wray,et al.  Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis , 2012, Human molecular genetics.

[11]  M. Gallagher,et al.  Age-Related Memory Impairment Is Associated with Disrupted Multivariate Epigenetic Coordination in the Hippocampus , 2012, PloS one.

[12]  E. Wijsman,et al.  Genome scan of age‐at‐onset in the NIMH Alzheimer disease sample uncovers multiple loci, along with evidence of both genetic and sample heterogeneity , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[13]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[14]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[15]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[16]  W. Chan,et al.  Apolipoprotein E Polymorphism and Age at Onset of Alzheimer’s Disease in a Quadriethnic Sample , 2011, Dementia and Geriatric Cognitive Disorders.

[17]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[18]  J. Marchini,et al.  Genotype imputation for genome-wide association studies , 2010, Nature Reviews Genetics.

[19]  Lennart Opitz,et al.  Altered Histone Acetylation Is Associated with Age-Dependent Memory Impairment in Mice , 2010, Science.

[20]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[21]  F. Coppedè,et al.  Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. , 2009, Mutation research.

[22]  D. Blacker,et al.  A genomic scan for age at onset of alzheimer's disease in 437 families from the NIMH genetic initiative , 2008, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

[23]  P. S. St George-Hyslop,et al.  Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer’s disease , 2008, Neurogenetics.

[24]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[25]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[26]  M. Owen,et al.  Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[27]  Peter P. Zandi,et al.  Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .

[28]  Eden R Martin,et al.  Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. , 2003, Human molecular genetics.

[29]  Rajesh Pahwa,et al.  Age at onset in two common neurodegenerative diseases is genetically controlled. , 2002, American journal of human genetics.

[30]  L Sun,et al.  Statistical tests for detection of misspecified relationships by use of genome-screen data. , 2000, American journal of human genetics.

[31]  Laura Fratiglioni,et al.  Worldwide Prevalence and Incidence of Dementia , 1999, Drugs & aging.

[32]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[33]  Janice E. Knoefel,et al.  Apolipoprotein E element 4 association with dementia in a population-based study , 1996, Neurology.

[34]  B. Tycko,et al.  Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease , 1995, Neurology.

[35]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[36]  R. D'Agostino,et al.  Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study , 1992, Neurology.

[37]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[38]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[39]  A. Singleton,et al.  TREM2 Variants in Alz hei mer's Disease , 2012 .

[40]  Nick C Fox,et al.  Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .

[41]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[42]  Wj Gauderman,et al.  QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies , 2006 .

[43]  E M Wijsman,et al.  The number of trait loci in late-onset Alzheimer disease. , 2000, American journal of human genetics.

[44]  R H Myers,et al.  Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. , 1996, Neurology.

[45]  Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.